{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:45:04Z","timestamp":1788857104101,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015669","name":"Laurentian University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008097","name":"Department of Family and Community Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","heartrhythmjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.hrthm.2024.08.033","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:59:54Z","timestamp":1724378394000},"page":"961-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-5111","authenticated-orcid":false,"given":"Mohammed","family":"Shurrab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Haldenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Baykaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis T.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2024.08.033_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/jcm7100338","article-title":"The CHA2DS2-vasc score predicts major bleeding in non-valvular atrial fibrillation patients who take oral anticoagulants","volume":"7","author":"Lee","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1160\/TH08-11-0730","article-title":"Bleeding with anticoagulation therapy\u2014who is at risk, and how best to identify such patients","volume":"102","author":"Palareti","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hrthm.2024.08.033_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.10.031","article-title":"Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation","volume":"186","author":"Shurrab","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2024.08.033_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010\u20132017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.hrthm.2024.08.033_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hrthm.2024.08.033_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.08.033_bib7","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamainternmed.2020.1835","article-title":"Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants","volume":"180","author":"Hill","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib8","article-title":"Rivaroxaban versus apixaban for stroke prevention in atrial fibrillation: an instrumental variable analysis of a nationwide cohort","volume":"13","author":"Bonde","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hrthm.2024.08.033_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064662","article-title":"Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study","volume":"12","author":"Jaksa","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.hrthm.2024.08.033_bib11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.hrthm.2024.08.033_bib12","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.hrthm.2024.08.033_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2024.06.010","article-title":"Comparative effectiveness and safety of apixaban and rivaroxaban in older patients with atrial fibrillation: a population-based cohort study","author":"Shurrab","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2024.08.033_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20064","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding","volume":"4","author":"Lip","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hrthm.2024.08.033_bib15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cjca.2016.06.006","article-title":"Identifying patients with atrial fibrillation in administrative data","volume":"32","author":"Tu","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.08.033_bib16","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.08.033_bib17","doi-asserted-by":"crossref","first-page":"574.e13","DOI":"10.1016\/j.amjmed.2017.11.046","article-title":"The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non\u2013vitamin K antagonist oral anticoagulants","volume":"131","author":"Lip","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004267","article-title":"Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation\u2013Thrombolysis in Myocardial Infarction 48)","volume":"10","author":"Link","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2024.08.033_bib19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib20","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib21","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib22","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"issue":"suppl","key":"10.1016\/j.hrthm.2024.08.033_bib23","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.08.033_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2024.08.033_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.hrthm.2024.01.025","article-title":"Comparison of different direct oral anticoagulant regimens in atrial fibrillation patients with high bleeding risk","volume":"21","author":"Ciou","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2024.08.033_bib26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2024.08.033_bib28","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.08.033_bib29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.08.033_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.08.033_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cjco.2021.09.002","article-title":"Association of sex with stroke and bleeding risk of apixaban and rivaroxaban in elderly atrial fibrillation patients using propensity score weights","volume":"4","author":"Gulilat","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.hrthm.2024.08.033_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2350","article-title":"Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation","volume":"40","author":"Perreault","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.hrthm.2024.08.033_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010\u20132020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527124031515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527124031515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:04:07Z","timestamp":1744455847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527124031515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1547527124031515"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2024.08.033","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2024.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}